Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

FDA accepts Hemispherx Biopharma's Ampligen NDA for review

July 10, 2008

New therapeutic agents for psychiatric disorders reported in recent patent literature

July 10, 2008

Amorfix on schedule to complete antibody infusion studies in mice of therapy for ALS

July 9, 2008

Teva reports results from phase III FORTE study of glatiramer acetate 40 mg in RRMS

July 9, 2008

Sciele Pharma completes phase III safety trial for glycopyrrolate and plans to file an NDA

July 9, 2008

Medivation reports positive results from phase II study of Dimebon in HD

July 9, 2008

Novel histamine H3 receptor inverse agonist profiled at Banyu

July 9, 2008

Labopharm reaquires U.K. sales and marketing rights to tramadol

July 8, 2008

New treatments for neurological disorders reported in recent patent literature

July 8, 2008

Tezampanel is safe and effectively treats acute migraine in a phase IIb study

July 8, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...